Friday, February 28, 2020
PharmD students Milena Ljumovic and Trisha Manucha present their PHARM401 research on the prevalence of off-label use for coagulation factors VIII and IX based on data from the Web-Accessible Population Pharmacokinetics Service – Hemophilia (WAPPS-Hemo.org). The results indicate that off-label use is higher for FIX (approx. 60%) than for FVIII (35%). Off-label use is higher in the region of Health Canada as compared to regions covered by the European Medicines Agency and the US Food & Drug Administration. Obese and overweight patients have a higher prevalence of off-label use as compared to average or underweight individuals.